cenerimod

Key facts

Mechanism of action

Sphingosine 1-phosphate receptor Edg-1 modulator

Primary target: Sphingosine 1-phosphate receptor 1

Approval history

1. Cenerimod Phase 3 · Viatris Pharmaceuticals Co · Lupus Erythematosus, Systemic
2. Cenerimod 4 mg Phase 3 · Viatris Pharmaceuticals Co · Systemic lupus erythematosus
3. Cenerimod 4 mg, Cenerimod matching placebo Phase 3 · Viatris Pharmaceuticals Co · Moderate to severe systemic lupus erythematosus
4. Cenerimod matching placebo, Cenerimod 4 mg Phase 3 · Viatris Pharmaceuticals Co · Moderate to severe systemic lupus erythematosus
5. ID-064-108 Phase 1 · Viatris Pharmaceuticals Co · Not applicable - healthy volunteer trial

1. ponesimod Antineoplastic and immunomodulating agents (L04)
2. etrasimod arginine Sphingosine 1-phosphate receptor Edg-6 modulator
3. ozanimod hydrochloride Sphingosine 1-phosphate receptor Edg-1 modulator
4. siponimod Antineoplastic and immunomodulating agents (L04)
5. etrasimod Antineoplastic and immunomodulating agents (L04)
6. siponimod fumaric acid Sphingosine 1-phosphate receptor Edg-1 agonist

Frequently asked questions